Techno Drugs Ltd.

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2026 at 4:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.

Refer to their earlier news disseminated by DSE on 07.10.2026 regarding clarification on recent news published in the online news and further query issued by DSE on October 13, 2026, the company has further informed, among others, the following: "...We did not publish a separate dissemination notification. This omission was purely unintentional. Mentionable that Our company primarily manufactures and supplies pharmaceutical items, specifically contraceptive (birth control) products, (cont.) (Cont. News of TECHNODRUG): which are historically sold through government tender processes. Over the last two years, sales through government tenders were temporarily halted, which severely impacted our cash flow and led to a delay in servicing our bank loan interest. Of the total interest amount of BDT 21.78 Crore, we have repaid BDT 8.80 Crore, leaving an overdue balance of BDT 12.98 Crore. Furthermore, we were unaware that the bank had initiated the auction process at that stage..." (end)

(Cont. News of TECHNODRUG): which are historically sold through government tender processes. Over the last two years, sales through government tenders were temporarily halted, which severely impacted our cash flow and led to a delay in servicing our bank loan interest. Of the total interest amount of BDT 21.78 Crore, we have repaid BDT 8.80 Crore, leaving an overdue balance of BDT 12.98 Crore. Furthermore, we were unaware that the bank had initiated the auction process at that stage..." (end)

In response to a DSE query letter dated October 06, 2026 regarding a news published in an online news titled "Techno Drugs' main factory up for auction, Tk. 203 crore in loan default (translated from Bengali to English)" on October 05, 2026, the company has informed the following: "Our company operates two manufacturing facilities located in Gazipur and Narsingdi. A significant portion of our manufactured (cont.1) (Cont. news of TECHNODRUG): medicines specifically Contraceptive (Birth Control) products has historically been sold through government tender processes. In the previous year, sales through Government tenders were temporarily halted, which adversely impacted the company's expected cash flow. As a consequence, there was a temporary delay in servicing our regular bank loan installments. Due to the delay in installment payments, the respective bank issued a notice, which (cont.2) (Cont. news of TECHNODRUG): was recently published in Daily Samakal. Please be informed that the management takes this matter with utmost seriousness. We are actively engaged in advanced bilateral negotiations with the bank to resolve the issue through by pay Cheque for loan Adjustment. (cont.3) (Cont. news of TECHNODRUG): Production activities across our factories remain operational. We anticipate that once the tender process resumes, the company's revenue stream and banking operations will swiftly normalize. We assure our valued shareholders, investors, and the DSE authorities that the management is taking all necessary and effective steps to resolve this temporary loan-related challenge at the earliest." (end)

(Cont. news of TECHNODRUG): Production activities across our factories remain operational. We anticipate that once the tender process resumes, the company's revenue stream and banking operations will swiftly normalize. We assure our valued shareholders, investors, and the DSE authorities that the management is taking all necessary and effective steps to resolve this temporary loan-related challenge at the earliest." (end)